{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:59:58Z","timestamp":1783792798209,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jvacx.2020.100060","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T11:03:54Z","timestamp":1586430234000},"page":"100060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile"],"prefix":"10.1016","volume":"5","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kortekaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Christofferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelle","family":"Desiree LaBeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Swanepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Ksiazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip R","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart T.","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-8710","authenticated-orcid":false,"given":"Brian H.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2020.100060_b0005","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3201\/eid1712.111035","article-title":"Molecular Epidemiology of Rift Valley Fever Virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0010","article-title":"Correction: Molecular Epidemiology of Rift Valley Fever Virus. Letter to the Editor","author":"Grobbelaar","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0015","first-page":"1","article-title":"Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.jvacx.2020.100060_b0020","series-title":"The propagation and modification of strains of Rift Valley fever viruses in embryonated eggs and their use as immunizing agents for domestic ruminants","author":"Kaschula","year":"1953"},{"key":"10.1016\/j.jvacx.2020.100060_b0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2020.100060_b0030","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","article-title":"NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription","volume":"78","author":"Billecocq","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2020.100060_b0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12985-016-0573-8","article-title":"Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins","volume":"13","author":"Ly","year":"2016","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.jvacx.2020.100060_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003550","article-title":"Randomized Controlled Field Trial to Assess the Immunogenicity and Safety of Rift Valley Fever Clone 13 Vaccine in Livestock","volume":"9","author":"Njenga","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2020.100060_b0045","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4102\/ojvr.v82i1.857","article-title":"Safety and immunogenicity of Onderstepoort Biological Products' Rift Valley fever Clone 13 vaccine in sheep and goats under field conditions in Senegal","volume":"82","author":"Lo","year":"2015","journal-title":"Onderstepoort J Vet Res"},{"issue":"3","key":"10.1016\/j.jvacx.2020.100060_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/vbz.2009.0246","article-title":"Replication of Clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, in Aedes and Culex mosquitoes","volume":"10","author":"Moutailler","year":"2010","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0070","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jvacx.2020.100060_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0080","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100060_b0085","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100060_b0090","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2020.100060_b0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0034-5288(92)90029-2","article-title":"Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine","volume":"52","author":"Baskerville","year":"1992","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.jvacx.2020.100060_b0100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turrell","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2020.100060_b0105","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm Protein of Rift Valley Fever Virus Suppresses Virus-Induced Apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J Virology"},{"key":"10.1016\/j.jvacx.2020.100060_b0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and Immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0115","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2020.100060_b0120","first-page":"401","article-title":"Evaluation of the Immunogenicity of a Mutagenized Rift Valley Fever MP-12 and a Recombinant Rift Valley Fever arMP12\u0394Nsm21\/384 Vaccine Candidates in Indigenous Species of Cattle, Sheep, and Goats in Tanzania","volume":"10","author":"Salekwa","year":"2019","journal-title":"J Vaccines Vaccinology"},{"key":"10.1016\/j.jvacx.2020.100060_b0125","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.vaccine.2019.01.067","article-title":"Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12DNSm21\/384 vaccine candidate for sheep, goats and calves","volume":"37","author":"Boumart","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2020.100060_b0130","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.jvacx.2020.100060_b0135","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.jvacx.2020.100060_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006474","article-title":"Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates","volume":"12","author":"Smith","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2020.100060_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002670","article-title":"Deletion of the NSm Virulence Gene of Rift Valley Fever Virus Inhibits Virus Replication in and Dissemination from the Midgut of Aedes aegypti Mosquitoes","volume":"8","author":"Kading","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0150","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1128\/JVI.00961-14","article-title":"Creation of Rift Valley Fever Viruses with Four-Segmented Genomes Reveals Flexibility in Bunyavirus Genome Packaging","volume":"88z","author":"Wichgers Schreur","year":"2014","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.jvacx.2020.100060_b0155","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.vaccine.2015.01.077","article-title":"Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination","volume":"33","author":"Wichgers Schreur","year":"2015","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.jvacx.2020.100060_b0160","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.vaccine.2017.04.024","article-title":"Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy","volume":"35","author":"Wichgers Schreur","year":"2017","journal-title":"Vaccine"},{"issue":"34(51)","key":"10.1016\/j.jvacx.2020.100060_b0165","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique Safety Issues Associated with Virus Vectored Vaccines: Potential for and Theoretical Consequences of Recombination with Wild Type Virus Strains","volume":"12","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0170","first-page":"616","article-title":"The use of vaccination in the control of bluetongue in southern Africa","volume":"40","author":"Dungu","year":"2004","journal-title":"Vet Ital"},{"key":"10.1016\/j.jvacx.2020.100060_b0175","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1016\/j.vaccine.2010.06.105","article-title":"In vivo cross-protection to African horse sickness serotypes 5 and 9 after vaccination with serotypes 8 and 6","volume":"28","author":"von Teichman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0180","doi-asserted-by":"crossref","unstructured":"Rodriguez L, Nogales A, Reilly EC, et al. A live-attenuated influenza vaccine for H3N2 canine influenza virus. 2017; 504: 96\u2013106.","DOI":"10.1016\/j.virol.2017.01.020"},{"issue":"10","key":"10.1016\/j.jvacx.2020.100060_b0185","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/v11100928","article-title":"Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines","volume":"11","author":"Rodriguez","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2020.100060_b0190","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004\u20132014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jvacx.2020.100060_b0195","article-title":"Reassortment of bluetongue virus vaccine serotypes in cattle","volume":"89","author":"Van den Bergh","year":"2018","journal-title":"J South Afr Vet Assoc"},{"key":"10.1016\/j.jvacx.2020.100060_b0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/1040841X.2016.1186005","article-title":"Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations","volume":"43","author":"Feemstra","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.jvacx.2020.100060_b0205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virusres.2008.05.016","article-title":"A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment","volume":"137","author":"Batten","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.jvacx.2020.100060_b0210","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2020.100060_b0215","doi-asserted-by":"crossref","first-page":"11152","DOI":"10.1128\/JVI.01519-08","article-title":"Multiple Virus Lineages Sharing Recent Common Ancestry Were Associated with a Large Rift Valley Fever Outbreak among Livestock in Kenya during 2006\u20132007","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2020.100060_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185194","article-title":"Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain","volume":"12","author":"Ly","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jvacx.2020.100060_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-018-1611-y","article-title":"Molecular aspects of Rift Valley fever virus and the emergence of reassortants","volume":"55","author":"Gaudreault","year":"2019","journal-title":"Virus Genes"},{"key":"10.1016\/j.jvacx.2020.100060_b0230","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2020.100060_b0235","unstructured":"Ikegami, T, Hill, TE, Smith, JK, FAO. Rift Valley fever vaccine development, progress and constraints. In: Proceedings of the GF-TADs meeting, January 2011, Rome, Italy. FAO Animal Production and Health Proceedings, No. 12. Rome, Italy, 2011."},{"issue":"46","key":"10.1016\/j.jvacx.2020.100060_b0240","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1016\/j.vaccine.2013.09.029","article-title":"Vaccines against diseases transmitted from animals to humans: a one health paradigm","volume":"31","author":"Monath","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2020.100060_b0245","series-title":"Replicating Vaccines-a New Generation","year":"2010"},{"key":"10.1016\/j.jvacx.2020.100060_b0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018","journal-title":"Curr Opin Virol"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136220300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:02:27Z","timestamp":1762912947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136220300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"alternative-id":["S2590136220300073"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100060","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2020.100060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100060"}}